IceCure Highlights Cryoablation Advances in Breast Cancer Care
Caesarea, Israel, August 13, 2026 IceCure Medical Ltd., a developer of minimally invasive cryoablation technology for tumor treatment, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Caesarea, Israel, August 13, 2026 IceCure Medical Ltd., a developer of minimally invasive cryoablation technology for tumor treatment, has...
BENGALURU, Karnataka, India, July 29, 2026 Biocon Limited has announced that its Canadian subsidiary has received Health Canada Notice...
CAESAREA, Israel, July 29, 2026 IceCure Medical Ltd. has announced a significant development that could broaden the role of...
CAESAREA, Israel, July 6, 2026 IceCure Medical Ltd. has announced accelerating commercial adoption of its ProSenseâ„¢ cryoablation system in...
CAESAREA, Israel, March 25, 2026 IceCure Medical has reported positive five-year top-line results from its ICESECRET clinical trial, demonstrating...
